KIF2C and breast carcinoma: Notably, KIF2C has been shown to enhance the malignancy of various tumors, including breast cancer, non‐small cell lung cancer (NSCLC), and hepatocellular carcinoma (HCC) [17], with elevated KIF2C expression correlating with poor overall survival and disease‐free survival [18, 19].